Zai Lab Limited Presents Positive Phase 1b Data for Lung Cancer Treatment
What happened
Zai Lab Limited presented results from a global Phase 1b clinical trial evaluating zoci plus atezolizumab for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) at the European Society for Medical Oncology Congress 2026. At the recommended Phase 3 dose, the combination achieved a confirmed objective response rate of 81.8% and an estimated 6-month progression-free survival rate of 81.9% in 1L ES-SCLC patients. The therapy was reported as well-tolerated.
Why it matters
The positive clinical outcomes for zoci plus atezolizumab in ES-SCLC could boost Zai Lab Limited's competitive position in the oncology market. The company also expects to initiate a global, randomized Phase 3 study by the end of 2026.
Who's involved
- Zai Lab LimitedPresented Phase 1b clinical trial data for zoci plus atezolizumab.
- European Society for Medical OncologyHosted the congress where Zai Lab Limited presented its scientific data.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Zai Lab LimitedSpeculative
Positive clinical data could boost future revenue potential.
- HKTSpeculative
May see its stock price impacted by Zai Lab Limited's positive clinical data presentation.
Keep exploring
The entities involved
-
Zai Lab Limited
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
Nothing else this week.
-
European Society for Medical Oncology
Professional organisation
Related events
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Hengrui Pharma and Guangdong Provincial People's Hospital presented research findings at the ESMO Congress on October 20, 2026.
- Bristol-Myers Squibb presented clinical data at the European Society for Medical Oncology (ESMO) Congress in Madrid.